MS-STAT2

Updates and insight on the MS-STAT2 study from the team at UCL. A phase 3 clinical trial of high dose simvastatin for secondary progressive multiple sclerosis

[MS Society UK @mssocietyuk]

Today the results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen.

This trial tested simvastatin, commonly used to treat high cholesterol, in 964 people with secondary progressive MS. (1/6)

[MS-STAT2 @MsStat2]

Registration and abstract submission are open for MS Frontiers conference!

This year the MS Society are hosting their MS research conference at the University of Liverpool.

Find out all about it and how to register via their website:

https://t.co/qfBKZ40Yri

[Klaus Schmierer @KlausSchmierer]

Thank you @StuStepsUp+Marie for inspiring work @mssocietyuk @mscymru Ambassadors for people with #MS #AdvancedMS Check out https://t.co/qmgDl2jQ6t #ChariotMS @QSMSCENTRE @MsStat2 @OctopusTrial @AttackMS_trial @the_MSBlog #MS @RachelHorne19 @themsguide @aid4disabled #NHS75 #GIG75

[OctopusTrial @OctopusTrial]

Excellent @EANeurology #EAN2023 update on our expanded knowledge of #MS CNS compartmentalised inflammation and the exciting near future of BTK Inhibitors by Wallace Brownlee, Veronica Popescu and Martin König

@DrWBRO @VeroPopescu

[Wallace Brownlee @DrWBRO]

Great to be in Budapest for #EAN2023 discussing PIRA, compartmentalized CNS inflammation and BTK inhibitors with Veronica Popescu and Marton König @VeroPopescu @EANeurology

[OctopusTrial @OctopusTrial]

What is MS progression? Our understanding of progress independent of disease activity (PIRA) has grown over the last 20 years, with clinical and real world studies confirming that once relapses are controlled with DMTs progression can still happen!

[OctopusTrial @OctopusTrial]

An excellent overview of #SMOULDERINGMS - how we see progression independent of relapses #PIRA, what processes are involved and what #biomarkers will let us ultimately lead to individualized treatment!

[OctopusTrial @OctopusTrial]

#BrainAtrophy and #CognitiveImpairment in #MS - Closely interlinked, and of great importance to PWMS. Cognitive impairment being associated with more care needs and worse quality of life - focus on slowing/stopping this is essential!

[OctopusTrial @OctopusTrial]

#BigData in #MS - a great overview of the incorporation of all the -omics (genomic, metabolomics, proteomics, etc) towards novel understanding and treatments for #PMS #ProgressiveMS

[OctopusTrial @OctopusTrial]

#BigData in #MS - so many exciting opportunities to dive deeper into phenotypes, personalised assessments, and enhance clinical trials!

[MS-STAT2 @MsStat2]

The European Academy of Neurology 2023 conference! Let's talk #MS #BigData #Biomarkers #SmoulderingMS #clinicaltrials #PIRA and much more!

[MS-STAT2 @MsStat2]

@cathyem1 Great question! It's very hard from a single study to be sure if it's

atrophy->CVR, or
CVR->atrophy, or
<->

There is a lot of evidence of CVR impacting brain function long term generally tho! More work is ongoing and we think simva might have a direct role in PMS protection!

[MS-STAT2 @MsStat2]

Hot off the press! The first STAT2 research paper - Cardiovascular Risk Factors in SPMS and how they impact brain volumes and memory.

https://t.co/LpNJzjby3F

Thank you to all our participants for their time and contribution!

[MS-STAT2 @MsStat2]

#MSAwarenessWeek - how does MS make you feel? Does it affect you personally, or someone you know?

Our amazing colleague Dr Alessia Bianchi @alessia_bia completing the London marathon to fundraiser for the @mssocietyuk!

If you'd like please donate via: https://t.co/68DsVJFFWK

[MS-STAT2 @MsStat2]

@aid4disabled @KlausSchmierer @QSMSCENTRE @QMULBartsTheLon @pctuqmul @SvetlanaMilca @AndreaStennett @Kimberley_AP @GavinGiovannoni @monicacmarta @mssocietyuk @Barts_Charity STAT2 has EDSS primary with many others, including 9HPT, 25FW, and the detailed BICAMS cognitive assessments as secondary outcomes.

OCTOPUS slightly complicated as multi-phase, but the phase 3 element likely to use a composite primary (EDSS, 9HPT and 25FW), similar to ASCEND.

[MS-STAT2 @MsStat2]

@aid4disabled Thank you Patrick !!

[MS-STAT2 @MsStat2]

@cathyem1 @Brandon_Beaber High levels of nerve damage detected in blood probably a bad thing whether on simvastatin or placebo. But the statin did preserve brain volume and performance on some thinking tests as well - so looked promising.

[MS-STAT2 @MsStat2]

@cathyem1 @Brandon_Beaber We will look at this again in STAT2, but need to wait for all the final visits to be completed first.

[MS-STAT2 @MsStat2]

@cathyem1 @Brandon_Beaber Hi Cathy. This analysis (using the previous MS-STAT1 trial data) showed that those with having higher levels of nerve damage in your blood at the beginning of the trial was associated with some worsening of cognition over the next 2 years.

[Dr. Brandon Beaber @Brandon_Beaber]

Higher serum neurofilament light chain (sNfL) is linked to more cognitive decline in MS. Data from the MS-STAT study (simvastatin vs. placebo in progressive MS) https://t.co/Dc167fdFHp